**Etavopivat Study for Blood Disorders** Etavopivat is a new medicine being tested for those with sickle cell disease or thalassemia, which are blood disorders that affect hemoglobin. Hemoglobin is a protein in your blood that helps carry oxygen around your body. This study will check how safe and effective etavopivat is over a long time. The study can last up to **264 weeks**, but it might end sooner if the medicine is approved in your country. To join, you need to already be part of another etavopivat study and must have seen benefits from it. If you had to stop or lower your dose during the other study, you need to be back on the full dose before joining this new one. You may still join if you are taking other medicines like hydroxyurea, as long as your dose has been stable. **Key Points:** - The study might last up to **264 weeks**. - Participants need to have shown benefits from etavopivat and be on a stable dose. - You can't join if you have other health issues that might affect safety or if you're on certain other medications. **Consider joining if you meet all the criteria and are interested in long-term treatment studies.**